国金证券股份有限公司 关于厦门唯科模塑科技股份有限公司 部分募投项目增加实施主体、实施地点事项的核查意见 国金证券股份有限公司（以下简称"保荐机构"）为厦门唯科模塑科技股份 有限公司（以下简称"唯科科技"或"公司"）首次公开发行股票并在创业板上 市的保荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证券交易所创业 板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》、《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》等有关规定，对唯科科技部分募投项目增加实施主体、实施地点的 事项进行了核查，核查情况如下： 单位：万元 | 序号 | 项目名称 | 拟使用募集资金金 | 已使用募集资金金额 | | --- | --- | --- | --- | | | | 1 | | | | | 额 | | | --- | --- | --- | --- | | 1 | 唯科高端智能模塑科技产业园项目 | 38,022.08 | 17,162.50 | | 2 | 唯科模塑智能制造项目 | 31,149.87 | 14,427.98 | | 3 | 唯科技术中心 ...

证券代码：301196 证券简称：唯科科技 公告编号：2023-070 厦门唯科模塑科技股份有限公司 关于部分募投项目增加实施主体、实施地点的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）于 2023 年 10 月 25 日召开第二届董事会第六次会议及第二届监事会第六次会议，审议通过了《关于 部分募投项目增加实施主体、实施地点的议案》，同意募投项目"唯科高端智能 模塑科技产业园项目"增加全资子公司泉州格兰浦模塑科技有限公司（以下简称 "泉州格兰浦"）、泉州唯科智能家居有限公司（以下简称"泉州智能家居"） 作为共同实施主体，募投项目"唯科模塑智能制造项目"增加厦门火炬高新区（翔 安）产业区春光路 1152 号、1154 号、1156 号、1166 号、1170 号为实施地点。 现将具体情况公告如下： 截至本公告披露日，公司募集资金用途计划及使用情况如下： 三、募投项目增加实施主体、实施地点的具体情况 | 序 号 | 项目名称 | 变更内容 | 变更前 | 变更后 | | --- | --- | --- | ...

证券代码：301196 证券简称：唯科科技 公告编号：2023-066 厦门唯科模塑科技股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）于 2023 年 4 月 25 日召开第二届董事会第三次会议、第二届监事会第三次会议及 2023 年 5 月 17 日召开 2022 年度股东大会，审议通过了《关于使用部分闲置募集资金进行现金 管理的议案》，同意在确保不影响募集资金投资项目建设和募集资金使用的情况 下，使用不超过 13 亿元（含）人民币的闲置募集资金进行现金管理，用于购买 安全性高、流动性好的保本型金融产品或结构性存款等理财产品，自公司股东大 会审议通过之日起 12 个月内（含）有效，在上述期限及额度内可循环滚动使用， 期满后归还至公司募集资金专用账户。公司独立董事、保荐机构均已发表明确同 意 意 见 。 具 体 内 容 详 见 公 司 2023 年 4 月 26 日 刊 登 于 巨 潮 资 讯 网 （www.cninfo.com.cn）的《关于使用部 ...

证券代码：301196 证券简称：唯科科技 公告编号：2023-065 厦门唯科模塑科技股份有限公司 关于使用部分闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）于 2023 年 4 月 25 日召开第二届董事会第三次会议及 2023 年 5 月 17 日召开 2022 年度股东大会， 审议通过了《关于使用部分闲置自有资金进行现金管理的议案》，同意公司使用 不超过人民币 9 亿元（含）的闲置自有资金进行现金管理，用于购买安全性高、 流动性好的金融产品或结构性存款等理财产品，使用期限为自公司股东大会审议 通过之日起不超过 12 个月（含）。在上述额度及决议有效期内，可循环滚动使 用。公司独立董事均已发表明确同意意见。具体内容详见公司 2023 年 4 月 26 日刊登于巨潮资讯网（www.cninfo.com.cn）上的《厦门唯科模塑科技股份有限 公司关于使用部分闲置自有资金进行现金管理的公告》。现将近期使用部分闲置 自有资金进行现金管理的情况公告如下： 一、新增现金管理的基本情 ...

Company Overview - The company's stock is listed on the Shenzhen Stock Exchange with the stock code 301196[17] - The company's legal representative is Zhuang Huiyang[17] - The company's foreign name is Xiamen Voke Mold & Plastic Engineering Co., Ltd.[17] - The company's foreign name abbreviation is VOKE[17] - The company's Chinese name is Xiamen Voke Mold & Plastic Engineering Co., Ltd.[17] - The company's Chinese abbreviation is Voke Technology[17] - The company's stock is traded under the name Voke Technology[17] - The company's stock is listed on the Shenzhen Stock Exchange[17] - The company's stock code is 301196[17] Financial Performance - Revenue for the reporting period increased by 13.78% to RMB 525,000,334.84 compared to the same period last year[22] - Net profit attributable to shareholders of the listed company decreased by 21.29% to RMB 58,633,001.27[22] - Net cash flow from operating activities decreased by 13.46% to RMB 111,075,921.43[22] - Total assets increased by 2.89% to RMB 3,480,522,207.86 compared to the end of the previous year[22] - Non-recurring gains and losses amounted to RMB 31,921,957.40, including government subsidies of RMB 14,199,367.22[26] - Revenue for the reporting period increased by 13.78% to 525,000,334.84 yuan compared to the same period last year[60] - Operating costs rose by 14.40% to 358,862,485.10 yuan, driven by business scale growth[60] - Sales expenses surged by 41.65% to 17,480,803.44 yuan due to increased business scale[60] - Management expenses increased by 55.65% to 76,139,068.78 yuan, mainly due to share-based payment expenses and new factory depreciation[60] - R&D investment grew by 12.06% to 31,997,517.48 yuan, reflecting continued focus on innovation[60] - Net cash flow from operating activities decreased by 13.46% to 111,075,921.43 yuan[60] - Net cash flow from investing activities improved by 73.97% to -260,999,314.95 yuan, primarily due to reduced cash management investments[60] - Net cash flow from financing activities dropped by 105.19% to -86,896,959.05 yuan, mainly due to the absence of IPO proceeds compared to the previous year[60] - Cash and cash equivalents decreased by 129.09% to -232,564,502.38 yuan, largely due to the absence of IPO proceeds[60] - The company's financial assets, including trading financial assets, totaled 1,155,843,962.70 yuan at the end of the reporting period[66] - The company invested a total of 116.4 million yuan in two manufacturing companies, Xiamen Tek Mold Industry Co., Ltd. (57.9 million yuan, 68.93% stake) and Wanxin (Xiamen) New Materials Co., Ltd. (58.5 million yuan, 30% stake)[72] - The total amount of funds raised by the company is 1.755 billion yuan, with 73.817 million yuan already invested and 105.798 million yuan remaining in the fundraising account[75][79] - The company used 1.36 billion yuan of idle funds for cash management, with a balance of 1.026 billion yuan in cash management as of June 30, 2023[77][79] - The company's high-end intelligent mold technology industrial park project has a total investment of 380.22 million yuan, with 153.9 million yuan already invested, achieving 40.48% of the planned progress[82] - The company's mold intelligent manufacturing project has a total investment of 311.49 million yuan, with 137.2 million yuan already invested, achieving 44.05% of the planned progress[82] - The company's technology center upgrade project has a total investment of 61.08 million yuan, with 11.5 million yuan already invested, achieving 18.83% of the planned progress[82] - The company's marketing service network construction project has a total investment of 22.17 million yuan, with 540,600 yuan already invested, achieving 2.44% of the planned progress[82] - The company's health appliance R&D incubation center project has a total investment of 90 million yuan, with 47.52 million yuan already invested[82] - The company's supplementary working capital project has a total investment of 580 million yuan, with 387.5 million yuan already invested, achieving 66.81% of the planned progress[82] - The company's total investment in fundraising projects is 1.444 billion yuan, with 738.17 million yuan already invested[82] - The company invested RMB 90 million in the construction of a health appliance R&D incubation center[83] - RMB 290 million of over-raised funds were used to permanently replenish working capital in 2022 and 2023[83] - The company changed the implementation location of the health appliance R&D incubation center project and replaced RMB 47.5239 million of over-raised funds with its own funds[83] - As of June 30, 2023, the company had cumulatively invested RMB 435.0239 million in over-raised funds[83] - The company used RMB 1.759651 billion of raised funds to replace pre-invested self-raised funds[83] - The company plans to use up to RMB 1.3 billion of idle raised funds for cash management[83] - As of June 30, 2023, the outstanding balance of cash management was RMB 1.026 billion[83] - The company's subsidiary Shanghai Kebi generated a net profit of RMB 12.493601 million[93] - The company's subsidiary Health Industry generated a net profit of RMB 6.3980024 million[93] - The company faces risks from fluctuations in raw material prices and has implemented measures to mitigate these risks[97] - Gross margin slightly decreased compared to the same period last year due to macroeconomic fluctuations, rising labor costs, raw material price volatility, and intensified market competition[98] - The company established subsidiaries in Germany, Malaysia, and Mexico to expand overseas markets, but faces risks from political, economic, and legal differences in international markets[99] - Rapid business expansion has led to challenges in production technology management, internal control processes, and human resource management[100] - The company's total assets increased to 3,480,522,207.86 yuan as of June 30, 2023, compared to 3,382,654,238.20 yuan at the beginning of the year[191][192] - Cash and cash equivalents decreased to 238,289,488.57 yuan from 472,412,595.13 yuan at the start of the year[191] - Trade receivables increased to 226,451,526.81 yuan from 217,241,333.43 yuan[191] - Inventory rose to 269,070,774.02 yuan from 235,035,440.14 yuan[191] - Long-term equity investments increased significantly to 78,308,298.87 yuan from 35,971,698.68 yuan[192] - Fixed assets grew to 784,287,998.25 yuan from 696,198,119.51 yuan[192] - Total liabilities increased to 482,145,361.60 yuan from 400,849,014.87 yuan[193] - Shareholders' equity slightly decreased to 2,998,376,846.26 yuan from 2,981,805,223.33 yuan[193] - The company's short-term borrowing increased to 2,002,000.00 yuan from zero at the beginning of the year[193] - Accounts payable rose to 193,720,470.50 yuan from 156,473,935.31 yuan[193] - Total operating revenue for the first half of 2023 reached 525,000,334.84 yuan, a 13.8% increase compared to 461,420,552.17 yuan in the same period last year[199] - Operating costs for the first half of 2023 were 484,735,600.60 yuan, up 21.6% from 398,496,947.81 yuan in the first half of 2022[199] - Net profit for the first half of 2023 was 59,986,656.11 yuan, a decrease of 19.4% compared to 74,429,260.94 yuan in the same period last year[200] - R&D expenses increased by 12.1% to 31,997,517.48 yuan in the first half of 2023, up from 28,553,076.96 yuan in the first half of 2022[200] - Total assets as of the end of the first half of 2023 were 2,923,584,018.09 yuan, a slight increase from 2,912,842,480.49 yuan at the end of the first half of 2022[196][197] - Accounts receivable decreased by 3.4% to 111,431,725.29 yuan at the end of the first half of 2023, down from 115,379,312.45 yuan at the end of the first half of 2022[196] - Inventory increased by 20.9% to 133,673,862.15 yuan at the end of the first half of 2023, up from 110,586,924.23 yuan at the end of the first half of 2022[196] - Long-term equity investments grew by 18.2% to 862,892,045.31 yuan at the end of the first half of 2023, compared to 729,716,368.90 yuan at the end of the first half of 2022[196] - Total liabilities decreased by 14.4% to 200,051,227.95 yuan at the end of the first half of 2023, down from 233,886,406.47 yuan at the end of the first half of 2022[197] - Shareholders' equity decreased slightly by 0.7% to 2,723,532,790.14 yuan at the end of the first half of 2023, compared to 2,741,688,698.24 yuan at the end of the first half of 2022[197] Business Operations - The company's main business includes the R&D, design, manufacturing, and sales of precision injection molds, extending to the production and sales of injection parts and health products[31] - The company has developed a "mold-plastic integration" production model, serving industries such as electronics, automotive, home appliances, and health products[31] - The company's product lines include precision injection molds, injection parts, and health products like air purifiers[31] - The company's production lines for precision injection molds, injection parts, and health products exhibit synergistic effects[44] - The company has accumulated 439 authorized patents, including 21 invention patents, supporting its long-term competitive advantage in precision injection mold design and processing[50] - The company operates production bases in Germany, Malaysia, and Mexico to enhance international market presence and leverage cost advantages[53] - The company's R&D expenses remain at a high level, with established provincial and national-level technology centers[50] - The company has a diversified product portfolio, extending from precision injection molds to injection parts and health products, covering markets such as electronics, automotive, home appliances, and health appliances[51] - The company has built a 100,000-class cleanroom and a central feeding system, equipped with advanced manufacturing and testing equipment, including five-axis CNC machining centers and optical measurement systems[52] - The company maintains long-term partnerships with major clients in electronics, automotive, home appliances, and health appliances, including Compal Group, IKEA Group, and Morning North Group[54] - The company has obtained ISO9001, IATF16949, and ISO13485 certifications, ensuring high-quality standards for its precision injection molds and injection parts[55] - The company employs a "direct sales" model for precision injection molds and injection parts, with a small portion using consignment sales[49] - The company uses a combination of ODM and OEM models for health product production, catering to brand clients' design and manufacturing needs[47] - The company adopts a "make-to-order" production model for precision injection molds and a "make-to-stock" model for injection parts, ensuring flexibility and efficiency[47] Corporate Governance and Shareholder Commitments - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserve into share capital[4] - The company held its 2023 First Extraordinary General Meeting on January 12, 2023, with a 62.01% investor participation rate, approving the 2022 Restricted Stock Incentive Plan[105] - On February 8, 2023, the company granted 3.662 million restricted shares to 240 eligible incentive recipients at a price of 17.92 yuan per share[109] - The company plans to distribute no cash dividends, no stock dividends, and no capital reserve to share capital conversion for the first half of the year[107] - The company has fulfilled its share lock-up commitments made during the IPO, with some commitments still in progress until 2025[118] - The company has made long-term commitments regarding competition, related transactions, and fund usage, which are currently being fulfilled[118] - The company has committed to not transferring or entrusting others to manage its shares directly or indirectly held before the IPO for 36 months from the date of listing[122] - The company has pledged to comply with all legal and regulatory requirements regarding shareholding and share changes, including reductions, and will bear corresponding legal responsibilities if these commitments are violated[123] - The company has established a mechanism to automatically extend the lock-up period by 6 months if the stock price falls below the IPO price for 20 consecutive trading days within 6 months post-listing[121] - The company has committed to not reducing its shareholding below 5% of the total shares during the lock-up period and will strictly follow legal procedures for any share reductions thereafter[122] - The company has promised to ensure stable control arrangements and continuous stable operation of the company when reducing pre-IPO shares after the lock-up period[121] - The company's controlling shareholder has committed not to transfer or entrust the management of shares held before the IPO for 36 months after the listing[124] - The controlling shareholder has also committed not to transfer or entrust the management of shares held before the IPO for 12 months after the listing[125] - The company will strictly comply with the post-listing articles of association and the three-year shareholder dividend return plan[125] - The controlling shareholder and their controlled enterprises currently do not engage in any business activities that compete with the company's main business[126] - The controlling shareholder will ensure the company's independence in assets, business, personnel, finance, and organization after the IPO[126] - The controlling shareholder will not use their position to engage in any activities that harm the interests of the company and other shareholders[127] - The controlling shareholder will not engage in any business activities that compete with the company's main business after the IPO[127] - The controlling shareholder will not use their position to influence the company's independence and will avoid significant related-party transactions[129] - The controlling shareholder will not use their position as a director/supervisor/senior manager to influence the company's independence[130] - The controlling shareholder has declared that there is currently no form of misappropriation or use of the company's funds[131] - The company will initiate a stock price stabilization plan if the stock price falls below the net asset value per share for 20 consecutive trading days within 36 months after the IPO[132] - The company's controlling shareholder will increase holdings by no less than RMB 5 million, with a maximum of 2% of the total shares within 12 months[133] - The company will repurchase shares through centralized bidding, with a single repurchase amount not less than 10% of the previous year's audited net profit and not exceeding 2% of the total shares[133] - The annual cumulative repurchase amount will not exceed 50% of the previous year's audited net profit[133] - The total repurchase amount will not exceed the total funds raised from the IPO[133] - Directors and senior executives will increase holdings by no less than 20% of their after-tax salary and cash dividends received from the company[133] - The company will implement measures such as profit distribution, capital reserve to share capital conversion, and cost reduction to stabilize the stock price[133] - The company will not transfer shares during the implementation of the stock price stabilization plan[133] - The company will publicly explain and apologize if it fails to implement the stock price stabilization measures[133] - The company's controlling shareholder, directors, and senior executives are obligated to fulfill the stock price stabilization commitments within 36 months after the IPO[133] - The company commits to refunding investors with the stock subscription amount plus bank deposit interest if the prospectus contains false statements or omissions before the stock is listed[134] - The company will repurchase all newly issued shares within 10 trading days if the prospectus contains false statements or omissions after the stock is listed, at a price not lower than the issuance price plus bank deposit interest[134] - The company will compensate investors for losses incurred due to false statements or omissions in the prospectus, in accordance with relevant laws and regulations[134] - The company guarantees that there is no fraudulent issuance in this offering and will repurchase all newly issued shares within 5 trading days if fraudulent issuance is confirmed[135] - The company's controlling shareholder and other related parties did not occupy non-operating funds during the reporting period[138] - The company had no illegal external guarantees during the reporting period[139] - The company's semi-annual financial report was not audited[141] - The company had no major litigation or arbitration matters during the reporting period[143] - The company had no significant related-party transactions during the reporting period[144] - The company had no significant contracts related to trusteeship, contracting, or leasing during the reporting period[150] Shareholder Structure - The company's limited-sale shares decreased by 5,975,000 shares, accounting for 4.79% of the total shares post-IPO, which became tradable on January 11, 2023[172] - The company's limited-sale shares decreased from 93,600,000 shares (75.00%) to 87,625,000 shares (70.21%) during the reporting period[172] - The company's unrestricted shares increased from 31,200,000 shares (25.00%) to 37,175,000 shares (29.

厦门唯科模塑科技股份有限公司 独立董事关于第二届董事会第五次会议相关事项的独立意见 根据《上市公司独立董事规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律、行政法规、规范性文件及《公 司章程》等有关规定，作为厦门唯科模塑科技股份有限公司（以下简称"公司"） 的独立董事，本着对公司、全体股东和投资者负责的态度，秉持实事求是的原则， 就公司第二届董事会第五次会议的相关事项发表如下独立意见： 一、关于《2023 年半年度募集资金存放与使用情况专项报告》的独立意见 经审议，我们认为：《2023 年半年度募集资金存放与使用情况专项报告》 真实、准确、完整地反映了公司 2023 年上半年的募集资金存放与使用情况,符合 中国证券监督管理委员会、深圳证券交易所对募集资金存放和使用的相关要求， 不存在违规使用募集资金的行为，亦不存在改变或者变相改变募集资金投向和损 害公司及中小股东利益的情形。 因此，我们一致同意公司对外报出《2023 年半年度募集资金存放与使用情 况专项报告》。 二、独立董事有关控股股东及其他关联方占用公司资金、公司对外担保情 况的专项说明和独立意见 根据《上市公司监 ...

证券代码：301196 证券简称：唯科科技 公告编号：2023-062 上述募集资金到账后，公司对募集资金的存放和使用进行专户管理，并与专 户银行、保荐机构签订了《募集资金三方监管协议》。 （二）2023 年半年度募集资金使用及结余情况 截止 2023 年 6 月 30 日，公司募集资金使用情况如下： 单位：元 （一）募集资金金额及到账情况 中国证监会 2021 年 12 月 1 日核发了《关于同意厦门唯科模塑科技股份有限 公司首次公开发行股票注册的批复》（证监许可[2021]3798 号），同意公司首 次公开发行股票的注册申请。根据上述批复，公司公开发行人民币普通股（A 股） 股 票 3,120 万 股 ，发 行 价格 为 64.08 元 / 股， 募 集资 金总额 为 人民 币 1,999,296,000.00 元，扣除与发行有关的费用（不含税）人民币 243,467,806.44 元后，实际募集资金净额为人民币 1,755,828,193.56 元。募集资金已于 2022 年 1 月 6 日划至公司本次公开发行开立的募集资金专项存储账户中，上述资金到账 情况已经大华会计师事务所（特殊普通合伙）验证并出具 ...

国浩律师（上海）事务所 关于厦门唯科模塑科技股份有限公司 调整 2022 年限制性股票激励计划授予价格 之 法律意见书 上海市北京西路 968 号嘉地中心 23-25 层 邮编：200041 23-25/F, Garden Square, 968 West Beijing Road, Shanghai 200041, China 电话/Tel: (+86)(21) 5234 1668 传真/Fax: (+86)(21) 5243 3320 网址/Website: http://www.grandall.com.cn 二〇二三年八月 | 释 | 义 | 1 | | --- | --- | --- | | 第一节 | 引言 | 2 | | 第二节 | 正文 | 4 | | 一、本次激励计划的批准和授权 | | 4 | | 二、关于本次调整事由及方法 | | 5 | | 三、本次激励计划的信息披露 | | 6 | | 四、结论意见 | | 6 | | 第三节 | 签署页 | 7 | 国浩律师（上海）事务所 法律意见书 释 义 除非另有说明，本法律意见书中相关词语具有以下特定含义： | 唯科科技、公司、本公 司、上市 ...

证券代码：301196 证券简称：唯科科技 公告编号：2023-064 厦门唯科模塑科技股份有限公司 关于调整 2022 年限制性股票激励计划授予价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日 召开了第二届董事会第五次会议和第二届监事会第五次会议，审议通过了《关于 调整 2022 年限制性股票激励计划授予价格的议案》，同意将 2022 年限制性股票 激励计划授予价格（含预留）由 17.92 元/股调整为 17.22 元/股。现将有关事项 说明如下： 一、本次激励计划已履行的相关审批程序 （一）2022 年 12 月 25 日，公司召开第一届董事会第二十一次会议，审议 通过了《关于<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于 <2022 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会 授权董事会办理股权激励相关事宜的议案》等相关议案，公司独立董事就本次激 励计划是否有利于公司的持续发展及是否存在损害公司及全体股东利益的情形 发表了 ...

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日召开第二届董事会第五次会议和第二届监事会第五次会议，审议通过了《关于 公司及子公司向银行申请综合授信额度的议案》，同意公司及子公司向银行申请 总额度不超过人民币 5 亿元的综合授信。具体内容公告如下： 证券代码：301196 证券简称：唯科科技 公告编号：2023-063 厦门唯科模塑科技股份有限公司 关于公司及子公司向银行申请综合授信额度的公告 （一）董事会审议情况 经审议，董事会认为：公司及子公司拟向银行申请总额度不超过人民币 5 亿 元的综合授信, 主要用于承兑汇票、保函、开立信用证、票据贴现、衍生产品外 汇交易等业务，符合公司业务发展的需要，有利于公司优化融资结构，财务风险 处于可有效控制范围内，不存在损害公司及中小股东利益的情形。同意公司及子 公司向银行申请综合授信额度。 （二）监事会审议情况 经审议，监事会认为：公司及子公司拟向银行申请总额度不超过人民币 5 亿 元的综合授信, 主要用于承兑汇票、保函、开立信用证、票据贴 ...